Nautilus Biotechnolgy, Inc. (NAUT)

Over the past six months, Nautilus Biotechnology, Inc.'s stock has been impacted by several events, including the Q3 2025 earnings report, which exceeded analysts' expectations, the successful installation and testing of its first external field evaluation unit at the Buck Institute for Research on Aging, and the launch of an Early Access Program for its novel proteomics platform. Nautilus Biotechnology regained Nasdaq compliance. The stock price as of January 9, 2026, was $2.06 per share, representing an increase of 17.05% over the past year, but decreased by 7.39% in the past month.

The provided information does not contain specific details regarding demand seasonality for Nautilus Biotechnology, Inc.'s products and services. Demand in this sector is often driven by research cycles, funding availability, and scientific advancements rather than typical consumer seasonality.

Nautilus Biotechnology, Inc. is a development-stage life sciences company focused on quantifying and unlocking the complexity of the proteome, operating within the Healthcare sector, specifically in the Biotechnology industry, and categorized under Life Sciences Tools and Services. Its core offering is the Nautilus Platform, a proteomics platform designed for high-resolution, single-molecule protein analysis, comprising instruments, consumables, and software analysis. Key products include the Proteome Analysis System and Reagent Kits, aiming to improve sensitivity, reproducibility, and throughput compared to traditional mass spectrometry approaches.

Nautilus Biotechnology, Inc. is headquartered in Seattle, Washington, United States. The provided search results do not detail a broader geographic footprint for the company's operations or market reach beyond its headquarters.

In the past year, Nautilus Biotechnology's reputation has been positively influenced by the successful installation and testing of its first field evaluation unit and the launch of an Early Access Program for its proteomics platform, demonstrating progress towards commercialization and validation of its technology. The company's focus on addressing emerging challenges in precision medicine and biomarker discovery also contributes to a forward-looking and positive brand image.

Nautilus Biotechnology, Inc. has a mixed ownership structure, with institutional investors holding approximately 39.48% to 45.19% of the company's stock, insiders owning around 35.50%, and public companies and individual investors holding approximately 1.80% to 32.39%. Major institutional owners include AH Capital Management, L.L.C., Perceptive Advisors Llc, Cercano Management LLC, Madrona Venture Group, LLC, Vanguard Group Inc, Comprehensive Financial Management LLC, Amazon Com Inc, Clarius Group, LLC, and Renaissance Technologies Llc. Parag Mallick is noted as owning the most shares among individuals.